Form 4: Y-mAbs Therapeutics Executive Thomas Gad Reports Stock and Option Grants

Y-mAbs Therapeutics Chief Business Officer Thomas Gad received stock and option grants, increasing his beneficial ownership in the company.

Summary

• Thomas Gad, Chief Business Officer of Y-mAbs Therapeutics, reported transactions involving the company's stock.
• On January 17, 2025, Gad received 32,000 restricted stock units (RSUs) and 64,000 stock options.
• The RSUs vest in three equal installments on January 17, 2026, 2027, and 2028.
• The stock options vest 25% on January 17, 2026, and then monthly until fully vested.
• Gad's total direct holdings after the transaction are 213,531 shares.
• He also has indirect ownership of 67,681 shares through GAD Enterprises LLC and 60,000 shares held by his children.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally positive for aligning interests but not a major market-moving event.

Positives

• The grant of RSUs and stock options aligns the executive's interests with the company's long-term performance.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the executive's continued service to the company.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector where long-term growth is a key focus.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of compensation for executives in the biotechnology industry.
• Companies like Amgen, Gilead, and Regeneron also use similar equity-based compensation plans to align executive interests with shareholder value.
• The vesting schedules are typical, with multi-year vesting periods to encourage long-term commitment.

Stakeholder Impact

• Shareholders may view this as a positive sign of aligning management's interests with the company's long-term success.
• Employees may see this as a standard practice for executive compensation.

Key Dates

Keywords

stock options, restricted stock units, insider trading, beneficial ownership, equity compensation, Form 4, Y-mAbs Therapeutics, Thomas Gad